
Precision Oncology & Functional Precision Medicine
Collaboration across patient-derived models, drug-response profiling, precision oncology and international technology development.
Integrated biotechnology development from translational research to product development and production.
Our Ecosystem
From biological mechanisms and molecular targets to translational experimental models.
Integrated molecular profiling and biomarker strategies for deeper biological insight.
From formulation concepts and biomaterials to functional validation and product-ready evidence.
Development of peptide, recombinant and biotechnology-derived products and intermediates.
In vitro, ex vivo and in vivo programs designed to evaluate efficacy, safety and biological performance.
Patient-derived models, precision medicine and biomarker-driven research for clinically relevant development.
From biological mechanisms and molecular targets to translational experimental models.
Integrated molecular profiling and biomarker strategies for deeper biological insight.
From formulation concepts and biomaterials to functional validation and product-ready evidence.
Development of peptide, recombinant and biotechnology-derived products and intermediates.
In vitro, ex vivo and in vivo programs designed to evaluate efficacy, safety and biological performance.
Patient-derived models, precision medicine and biomarker-driven research for clinically relevant development.
Our Ecosystem
Integrated scientific and development capabilities spanning discovery, validation, product development and clinical translation.
We develop biologically relevant experimental systems that connect fundamental mechanisms with translational research and downstream development.
Selected Project Portfolio
27 programmes
Selected programs spanning precision oncology, preclinical development, neuroimmune biology, product innovation and biotechnology raw materials.
Filters
Selected Partnerships
We collaborate with technology, industry and innovation partners to turn scientific progress into real-world solutions.

Collaboration across patient-derived models, drug-response profiling, precision oncology and international technology development.

Strategic collaboration spanning product development, preclinical and clinical research, biological validation and industry translation.

An innovation environment supporting biotechnology development, entrepreneurship, infrastructure access and collaborative R&D.
Insights & News
The talks, partnerships and science behind our work.
On stage and in the field — international conferences, congresses and invited lectures.
Best Abstracts Session
Our work on NMDAR1A- and IL-10-centered neuroimmune targeting in chronic pancreatitis has been selected for oral presentation in the Best Abstracts · Chronic Pancreatitis session at the EPC / IAP Joint Meeting 2026 in Istanbul.
Read full page→Chronic Pancreatitis · Pain Biology
An oral lecture on targeting NMDA Receptor 1A to ameliorate pain in chronic pancreatitis, marking a major milestone after three consecutive years of EPC visibility.
Read full page→Neuroimmune Targeting · Monoclonal Antibody
A hybridoma-derived CX3CR1-targeting monoclonal antibody strategy was presented as an oral presentation, highlighting neuroimmune pain modulation in pancreatic disease.
Read full page→Neuroimmune Targeting · Monoclonal Antibody
A hybridoma-derived CX3CR1-targeting monoclonal antibody strategy was presented as an oral presentation at the European Federation of Immunological Societies, highlighting neuroimmune pain modulation in pancreatic disease.
Read full page→Flash Talk Under Review
Our study on the transition from chronic pancreatitis to pancreatic cancer was accepted for poster presentation with travel grant support, focusing on TG2 fibrosis, senescence and neuroimmune pain.
Read full page→Nerve–Tumour–Immune Crosstalk
Our poster explored how NMDA receptor signalling may shape the dialogue between nerves, tumour cells and immune cells in pancreatic cancer and chronic pancreatitis.
Read full page→European Association for Cancer Research
Imperion co-founders Deniz Baybağ and Nedim Can Çevik were selected as EACR Ambassadors, supporting the visibility of cancer research opportunities and scientific networks across Europe.
Read full page→Featured Alongside Leading Industry Names
Imperion Biotechnology joined geneXplore as a featured participant alongside major names including AstraZeneca, Novartis, Atabay Biotechnology and Nobel İlaç.
Read full page→Students · Researchers · Translational Biotechnology
Imperion co-founders were invited to share the company’s story, scientific direction and translational biotechnology vision with students and young researchers.
Read full page→FAQ
A few things to know about working with Imperion.
We can contribute from early scientific concept and model development through preclinical validation, clinical translation, product development and scale-up planning. Our role is defined according to the current stage and development needs of each program.
Have a different question?
We're happy to discuss your needs.
Let's Work Together
Tell us where your program stands and where it needs to go. We'll help define the most effective development pathway.